Cantor Fitzgerald maintains Overweight rating on Celldex Therapeutics, $72 price target
Cantor Fitzgerald kept its Overweight rating on Celldex Therapeutics with a $72 price target, implying a 90% upside from the Sep 21 close. The firm cited strong clinical data and substantial market potential for the company's therapies, particularly in treating severe angioedema and chronic spontaneous urticaria.
How this was made
The 30-second read
Why it matters
Analyst maintains Overweight; price target implies 90% upside from recent close.
Market read
Rating reaffirmation offers limited trading impetus.
What to watch
Potential upcoming trial data could change outlook, but not reflected here.
Background
Celldex Therapeutics (CLDX) is a biotech focused on mast cell-mediated diseases.
Ticker impact
Cantor Fitzgerald maintained Overweight rating on Celldex Therapeutics with a $72 price target.
limited upside potential, likely muted market reaction
No new fundamental data; only a rating reaffirmation.
Market effects
Minimal impact on biotech sector; rating reaffirmation does not shift sector sentiment.
No regional effect.
Low relevance globally.
Counterpoint
Rating unchanged may signal lack of conviction; investors could wait for new data.
Key entities
- companyCelldex Therapeutics
Biotech firm developing therapies for angioedema and urticaria.
- analystCantor Fitzgerald
Equity research firm providing the rating.
